Immunotherapy for acute myelogenous leukaemia: a controlled clinical study 2 1/2 years after entry of the last patient.
about
Short-term treatment for acute myelogenous leukaemiaClinical significance of plasmacytosis in the day+14 bone marrow of patients with acute myeloid leukaemia undergoing induction chemotherapy.Immunotherapy alone vs no maintenance treatment in acute myelogenous leukaemia.Further evidence of response by leukaemia patients in remission to antigen(s) related to acute myelogenous leukaemia.Autologous leukemia-specific T-cell-mediated lymphocytotoxicity in patients with acute myelogenous leukemia.Therapeutic opportunities and targets in childhood leukemia.Therapeutic use of Aldara in chronic myeloid leukemia.Translational mini-review series on vaccines: Peptide vaccines for myeloid leukaemias.Is it important to decipher the heterogeneity of "normal karyotype AML"?Immunotherapy prospects for acute myeloid leukaemia.Clinical evaluation of cellular immunotherapy in acute myeloid leukaemia.Dendritic cell vaccine against leukemia: advances and perspectives.Spontaneous remission of acute myeloid leukemia.Remission-induction regimens in acute nonlymphocytic leukemia.PD-1 signaling and inhibition in AML and MDS.The clinical potential of interleukin-2.Active immunotherapy in acute myelogenous leukaemia and the induction of second and subsequent remissions.Immunotherapy of leukaemias: present status and future prospects.Surface antigens in acute myeloblastic leukaemia: a study using heterologous antisera.Immunotherapy in the treatment of acute myelogenous leukemia (AML): rationale, results and future prospects.Advances in the management of adult acute myelogenous leukaemia.Prolonged remission maintenance in acute myeloid leukaemia.
P2860
Q34759108-72989A30-12FB-494F-A426-F12AF974AB92Q36014322-ADA3B3D8-FBEB-43E4-93C2-E3589B107E63Q36043767-6D4C8511-C0AC-4055-967C-F45B4EB2C8D0Q36068942-997DF873-D34F-4949-A198-4F5BE28A76DBQ36340009-CD6E794D-9BEB-49A2-8BB6-9773FE44CEF8Q36585598-228DF145-3C86-4F43-8E4F-C7434B04A369Q36718548-F496EA29-766C-433B-98C8-F9D3B4B3951CQ36793112-44C87B6A-0A7B-4C48-AA67-F428868165C1Q37110802-110244BB-F650-4C69-9887-0F2F44ED16D5Q37763280-57F04588-1D6C-4B46-9954-7D530D6E70A4Q37868974-BDF96E51-8A17-49C2-B8DC-70ADE8D2E69DQ38210813-E3C54E02-D7E3-4979-A327-F666C6656308Q38256921-826E1288-5324-462B-BE1E-DC44A2BC45CEQ39337855-78EEABD2-A90F-4B6A-80B5-6B4F705B130BQ39393084-130D3DF8-8D85-485F-9927-E7AE73E9352BQ39550760-19D0B178-6E41-4AE4-874A-60FA784730F0Q40521351-E87B8046-7B30-4AC4-A044-45FA7EFC6312Q40561429-2A0CE9A6-21E3-469F-B5FB-01EE8286F3D4Q40570038-1D24C0B0-CA4D-487F-B744-5DCD759BEFB3Q41440933-4959CC62-A274-43C8-9DCE-3C45AE29DD27Q55404609-81931A6D-0AAC-4051-AFC5-E7F8A547F56DQ55440645-0901F4C5-9353-45F4-8777-629ADD283C9B
P2860
Immunotherapy for acute myelogenous leukaemia: a controlled clinical study 2 1/2 years after entry of the last patient.
description
1977 nî lūn-bûn
@nan
1977年の論文
@ja
1977年論文
@yue
1977年論文
@zh-hant
1977年論文
@zh-hk
1977年論文
@zh-mo
1977年論文
@zh-tw
1977年论文
@wuu
1977年论文
@zh
1977年论文
@zh-cn
name
Immunotherapy for acute myelog ...... ter entry of the last patient.
@ast
Immunotherapy for acute myelog ...... ter entry of the last patient.
@en
type
label
Immunotherapy for acute myelog ...... ter entry of the last patient.
@ast
Immunotherapy for acute myelog ...... ter entry of the last patient.
@en
prefLabel
Immunotherapy for acute myelog ...... ter entry of the last patient.
@ast
Immunotherapy for acute myelog ...... ter entry of the last patient.
@en
P2093
P2860
P921
P356
P1476
Immunotherapy for acute myelog ...... ter entry of the last patient.
@en
P2093
Alexander P
Crowther D
Whitehouse JM
P2860
P2888
P304
P356
10.1038/BJC.1977.38
P407
P577
1977-03-01T00:00:00Z